Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Cangene wins Health Canada OK for hepatitis B drug Add to ...

Cangene Corp. has received conditional Health Canada approval of its HepaGam B product to fight hepatitis B after liver transplants.

Cangene said Monday the notice of compliance covers prevention of hepatitis B recurrence following liver transplantation in adults with low levels of virus replication, and requires the company to continue a confirmatory clinical study.

HepaGam B, an immune globulin injection, is the only intravenous product licensed in Canada for this treatment.

Hepatitis B, which damages the liver, can recur after a liver transplant as a result of infection of the liver graft by virus that remained in circulation in the body.

"There are currently no other products licensed in Canada to prevent hepatitis B recurrence following liver transplantation and we are pleased to be able to answer the unmet medical need faced by these patients," stated Cangene CEO John Langstaff.

09:36ET 22-01-07

Follow us on Twitter: @GlobeBusiness

 

In the know

Most popular video »

Highlights

More from The Globe and Mail

Most Popular Stories